

NZX Announcement

5 August 2020

TruScreen strengthens its market presence in central and eastern Europe

As part of the rationalisation of its distributors network, **Truscreen Limited (NZX: TRU)** (“the Company”) is pleased to announce that it has appointed prominent medical device distributor Aspronix, s.r.o (Aspronix) as its exclusive distributor for Czech Republic, Slovakia, and Poland.

The territories of Czech Republic, Slovakia, and Poland, have a combined cervical cancer addressable screening population of over 17.9¹ million women, presenting a significant market opportunity for the Company.

Aspronix is a well-established specialised medical device distributor based in Prague, with a rapidly growing turnover and increasing presence in central and eastern Europe.

Together with Aspronix, the Company will develop a comprehensive market access plan and have begun preliminary Key Opinion Leaders (KOL) engagement for the region.

Truscreen CEO, Victoria Potarina, said *“The distribution agreement with Aspronix will enable us to significantly expand our distribution capabilities in central and eastern Europe, bringing Truscreen’s latest real-time cervical cancer screening technology to the women of Czech Republic, Slovakia and Poland.*

The rationalisation of our distributor portfolio will see established and committed medical device distributors, like Aspronix partnering with Truscreen to bring our Truscreen cervical cancer screening technology to the millions of women who are currently not covered by effective cervical cancer screening.”

- ENDS -

For more information, visit www.truscreen.com or contact:

Victoria Potarina
Chief Executive Officer
victoriapotarina@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

1. <https://www.cia.gov/library/publications/the-world-factbook/>

About TruScreen:

TruScreen is a Cervical Cancer Screening Device which offers the latest technology in cervical screening, providing real-time, accurate detection of pre-cancerous and cancerous cervical cells to help improve the health and well-being of women around the world. TruScreen's real-time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated proprietary algorithm framework is utilised to detect pre-cancerous change, or cervical intra-epithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue.



TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing issues with Pap tests, including failed samples, poor patient follow-up, patient discomfort and the need for supporting laboratory infrastructures. As such, TruScreen's target market is low- and middle-income countries where no large-scale cervical cancer screening programs and infrastructure are in place, such as China, Mexico, Africa, Russia and India. TruScreen's cervical cancer screening device is CE-marked and certified for use throughout Europe and CFDA-approved for sale in China. The global market potential for TruScreen is significant.

For more information, visit our website at www.truscreen.com

Watch our video on TruScreen: <http://truscreen.com/truscreen-the-company/truscreen-ultra-video/>